For Immediate Release:June 23, 2022
Today, the U.S. Food and Drug Administration issued
marketing denial orders (MDOs) to JUUL Labs Inc. for all of their products currently marketed in the United States. As a result, the company must stop selling and distributing these products. In addition, those currently on the U.S. market must be removed, or risk enforcement action. The products include the JUUL device and four types of JUULpods: Virginia tobacco flavored pods at nicotine concentrations of 5.0% and 3.0% and menthol flavored pods at nicotine concentrations of 5.0% and 3.0%. Retailers should contact JUUL with any questions about products in their inventory.
βTodayβs action is further progress on the FDAβs commitment to ensuring that all e-cigarette and electronic nicotine delivery system products currently being marketed to consumers meet our public health standards,β said FDA Commissioner Robert M. Califf, M.D. βThe agency has dedicated significant resources to review products from the companies that account for most of the U.S. market. We recognize these make up a significant part of the available products and many have played a disproportionate role in the rise in youth vaping.β
These MDOs only pertain to the commercial distribution, importation and retail sales of these products, and do not restrict individual consumer possession or useβthe FDA cannot and will not enforce against individual consumer possession or use of JUUL products or any other tobacco products.
After reviewing the companyβs
premarket tobacco product applications (PMTAs), the FDA determined that the applications lacked sufficient evidence regarding the toxicological profile of the products to demonstrate that marketing of the products would be appropriate for the protection of the public health. In particular, some of the companyβs study findings raised concerns due to insufficient and conflicting data β including regarding genotoxicity and potentially harmful chemicals leaching from the companyβs proprietary e-liquid pods β that have not been adequately addressed and precluded the FDA from completing a full toxicological risk assessment of the products named in the companyβs applications.